Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects

British Journal of Clinical Pharmacology

Volumn 73, Issue 5, 2012, Pages 706-716

  Li, Gai Ling ^a   Winter, Helen ^b   Arends, Rosalin ^b   Jay, Gary W ^b   Le, Vu ^c   Young, Tim ^a   Huggins, John P ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c PFIZER INC   (United States)

Author keywords

Fatty acid amide; Fatty acid amide hydrolase 1 (FAAH1); Irreversible inhibitor; PF 04457845; Pharmacokinetics

Indexed keywords

FATTY ACID AMIDASE; FATTY ACID AMIDASE 1; FATTY ACID AMIDASE INHIBITOR; PF 04457845; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; HEADACHE; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STEADY STATE; TREATMENT DURATION;

ADULT; AMIDOHYDROLASES; ANALYSIS OF VARIANCE; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; UREA; YOUNG ADULT;

EID: 84858954657     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04137.x     Document Type: Article

References (27)

1. Rice ASC, Lever I, Zarnegar R. Cannabinoids and analgesia, with special reference to neuropathic pain. In: Systematic Reviews in Pain Research: Methodology Refined, eds McQuay HJ, Kalso E, Moore RA. Seattle, WA: IASP Press, 2008; 233-46.
2. Ware MA, Tawfik BL. Safety issues concerning the medical use of cannabis and cannabinoids. Pain Res Manag 2005; 10: (Suppl. A): 31A-7A.
3. Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008; 108: 1687-707.
4. Ahn K, Johnson DS, Cravatt BF. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin Drug Discov 2009; 4: 763-84.
5. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98: 9371-6.
6. Lichtman AH, Shelton CC, Advani T, Cravatt BF. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 2004; 109: 319-27.
7. Wise LE, Shelton CC, Cravatt BF, Martin BR, Lichtman AH. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydolase and cannabinoid CB1 receptors. Eur J Pharmacol 2007; 557: 44-8.
8. Huitron-Resendiz S, Sanchez-Alavez M, Wills DN, Cravatt BF, Henriksen SJ. Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase. Sleep 2004; 27: 857-65.
9. Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, Wilkie GD, Austin BJ, Patricelli MP, Cravatt BF. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 2000; 97: 5044-9.
10. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, Breitenbucher JG, Chaplan SR, Webb M. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 2006; 148: 102-13.
11. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, Cravatt BF. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 2004; 311: 441-8.
12. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81.
13. Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A, Tontini A, Mor M, Tarzia G, Calignano A, Piomelli D. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 2007; 322: 236-42.
14. Johnson DS, Stiff C, Lazerwith SE, Kesten SR, Fay LK, Morris M, Beidler D, Liimatta MB, Smith SE, Dudley DT, Sadagopan N, Bhattachar SN, Kesten SJ, Nomanbhoy TK, Cravatt BF, Ahn K. Discovery of PF-04457845: a highly potent, orally bioavailable and selective urea FAAH inhibitor. ACS Med Chem Lett 2011; 2: 91-6.
15. Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, Young T, Wren P, Zhang Y, Swaney S, Van Becelaere K, Blankman JL, Nomura DK, Bhattachar SN, Stiff C, Nomanbhoy TK, Weerapana E, Johnson DS, Cravatt BF. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective FAAH inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther 2011; 338: 114-24.
16. US Department of Health and Human Services, US Food and Drug Administration. Guidance for Industry. Food-effect bioavailability and fed bioequivalence studies. 2002. 1-12. Available from (last accessed May 2011).
17. Yapa U, Prsakiewicz JJ, Wrightstone AD, Christine LJ, Palandra J, Groeber E, Wittwer AJ. HPLC-MS/MS assay of fatty acid amide hydrolase (FAAH) in blood: FAAH inhibition as clinical biomarker. Anal Biochem 2011. DOI: 10.1016/j.ab.2011.10.042.
18. Palandra J, Prusakiewicz J, Ozer JS, Zhang Y, Heath TG. Endogenous ethanolamide analysis in human plasma using HPLC tandem MS with electrospray ionization. J Chromatogr B 2009; 877: 2052-60.
19. Collie A, Maruff P, Snyder PJ, Darekar MA, Huggins JP. Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study. Hum Psychopharmacol 2006; 21: 481-8.
20. Collie A, Darekar A, Weissgerber G, Toh MK, Snyder PJ, Maruff P, Huggins JP. Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated Phase I study. Contemp Clin Trials 2007; 28: 391-400.
21. 1, TRPV1 and PPARγ receptors and neurotrophic factors. Pain 2008; 139: 541-50.
22. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-68.
23. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994; 56: 248-52.
24. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol 1999; 47: 53-8.
25. Bisogno T, De Petrocellis L, Di Marzo V. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des 2002; 8: 125-33.
26. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther 1998; 64: 636-47.
27. Swinney DC. Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 2004; 3: 801-8.